Barriers to utilization of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction in the outpatient setting: A single center analysis

Abstract

Background In patients with heart failure with reduced ejection fraction (HFrEF), SGLT2 inhibitors have consistently demonstrated improved cardiovascular and renal outcomes regardless of diabetes status. However, SGLT2i remain significantly under-utilized in this patient population. We seek to study the current state of SGLT2i use and barriers to utilization using real- world data in an inner -city community hospital setting.